Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
| Autor: | Johnny Boustany, Raghid El Khoury, Walid El Khoury, Ziad El Khoury, Maher Abdessater, Charbel El Hachem |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Metastatic/Recurrent medicine.medical_specialty Cabozantinib medicine.medical_treatment Case Report clear cell renal carcinoma urologic and male genital diseases law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial cabozantinib law Renal cell carcinoma Medicine sarcomatoid dedifferentiation business.industry Standard treatment Immunotherapy medicine.disease Nephrectomy Surgery 030104 developmental biology Oncology chemistry 030220 oncology & carcinogenesis Metastasectomy metastasectomy business |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.27543 |
| Popis: | Renal cell carcinoma with sarcomatoid dedifferentiation is an entity of RCC that has undergone an anaplastic transformation with both a carcinomatous and a sarcomatous component. The standard treatment in metastatic patients is immunotherapy. The aim of this article is to describe our case of metastatic recurrent RCC with sarcomatoid dedifferentiation in a 59 year old male patient treated with nephrectomy and multiple metastasectomies followed by Cabozantinib. Consecutive PET-CT scans showed no evidence of recurrence, three years after the last metastasectomy, and the patient is having currently a normal life. Sarcomatoid dedifferentiation remains a poor prognosis factor in RCC. Surgery for metastases followed by Cabozantinib may be a therapeutic option in metastatic young patients. However, a prospective randomized trial would be the best option to validate this approach. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|